CN103635185A - Eye fatigue suppression composition and food and drink containing same - Google Patents
Eye fatigue suppression composition and food and drink containing same Download PDFInfo
- Publication number
- CN103635185A CN103635185A CN201280031891.6A CN201280031891A CN103635185A CN 103635185 A CN103635185 A CN 103635185A CN 201280031891 A CN201280031891 A CN 201280031891A CN 103635185 A CN103635185 A CN 103635185A
- Authority
- CN
- China
- Prior art keywords
- resveratrol
- asthenopic
- compositions
- eye fatigue
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 26
- 230000001629 suppression Effects 0.000 title abstract 4
- 235000013305 food Nutrition 0.000 title description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 72
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 72
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 72
- 229940016667 resveratrol Drugs 0.000 claims abstract description 72
- 230000000694 effects Effects 0.000 claims description 26
- 238000010521 absorption reaction Methods 0.000 claims description 14
- 235000005911 diet Nutrition 0.000 claims description 12
- 230000037213 diet Effects 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 abstract description 13
- 238000011160 research Methods 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 238000012360 testing method Methods 0.000 description 24
- 235000010208 anthocyanin Nutrition 0.000 description 13
- 239000004410 anthocyanin Substances 0.000 description 13
- 229930002877 anthocyanin Natural products 0.000 description 13
- 150000004636 anthocyanins Chemical class 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 12
- 240000001890 Ribes hudsonianum Species 0.000 description 12
- 235000001466 Ribes nigrum Nutrition 0.000 description 12
- 235000009508 confectionery Nutrition 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 235000015218 chewing gum Nutrition 0.000 description 6
- 229940112822 chewing gum Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 210000000744 eyelid Anatomy 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000035807 sensation Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010049565 Muscle fatigue Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000007427 paired t-test Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 2
- 235000009392 Vitis Nutrition 0.000 description 2
- 241000219095 Vitis Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZOQQFMKYEOHRMC-KFOCXKDFSA-N (2r,3r,4r,5r,6s)-2-[[(2r,3s,4s,5r,6s)-6-[5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chromenylium-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-methyloxane-3,4,5-triol;chloride Chemical compound [Cl-].O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=C(O)C=2)O1 ZOQQFMKYEOHRMC-KFOCXKDFSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 1
- USNPULRDBDVJAO-YRBSALHSSA-O Cyanidin 3-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](Oc2c(-c3cc(O)c(O)cc3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 USNPULRDBDVJAO-YRBSALHSSA-O 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- PDHAOJSHSJQANO-OWOJBTEDSA-N Oxyresveratrol Chemical compound OC1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 PDHAOJSHSJQANO-OWOJBTEDSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- PLKUTZNSKRWCCA-NQWUONRPSA-O Tulipanin Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(-c3cc(O)c(O)c(O)c3)[o+]c3c(c(O)cc(O)c3)c2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 PLKUTZNSKRWCCA-NQWUONRPSA-O 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 1
- USNPULRDBDVJAO-FXCAAIILSA-O cyanidin 3-O-rutinoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(=[O+]C3=CC(O)=CC(O)=C3C=2)C=2C=C(O)C(O)=CC=2)O1 USNPULRDBDVJAO-FXCAAIILSA-O 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- XENHPQQLDPAYIJ-PEVLUNPASA-O delphinidin 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC(O)=C(O)C(O)=C1 XENHPQQLDPAYIJ-PEVLUNPASA-O 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960001331 keracyanin Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004310 photopic vision Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
- A23G4/068—Chewing gum characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Confectionery (AREA)
Abstract
The present invention provides an eye fatigue suppression composition having resveratrol as an active ingredient. As a result of extensive research, the inventors of the present invention discovered that resveratrol has an eye fatigue suppression effect and brought to fruition this eye fatigue suppression composition having resveratrol as an active ingredient. This composition is absorbed through the oral cavity and acts immediately to suppress eye fatigue.
Description
Technical field
The diet product that the present invention relates to alleviate asthenopic compositions and contain said composition.The invention further relates to eyestrain's onset at once, and take and used as the above-mentioned composition of feature and the diet product that contain said composition by the form of buccal absorption.
Background technology
About eyestrain, (non-patent literatures 1,2) such as reports of EMF Professional Committee of JEITA of civic organization is following explanation.The fatigue of the eyes that eyestrain refers to that eyelid is heavy, blurred vision etc. is general, can recover in the short period by certain rest.It is tired that asthenopic accumulation can develop into optic nerve.Optic nerve is tired is the significant a kind of morbid state of fatigue state, even if having a rest, also can not recover.Long-time with eye, can cause eye, nasion portion, frons sense of discomfort, compressing, headache, vision decay, dizzy, feel sick etc.
Specifically, eyestrain comprises to focal adjustments function and brings the eye such as ciliary muscle of impact to regulate the muscle fatigue of system and to cognitive function, bring this 2 class of central fatigue of the Vision information processing of impact.One of reason of the muscle fatigue of eye adjusting system can exemplify and continue for a long time to watch attentively in-plant object.If watch for a long time the closer objects such as PC display or book attentively, the tense situation of the specific muscle of eye continues, and muscle fatigue photosynthetic matter accumulation, shows with asthenopic form.Achievement of the present invention relates to eyestrain.
Alleviate asthenopic importance
In recent years, complain that asthenopic people is more and more, wish to find its solution, developed for this reason and given the commodity of warming or creeping chill, the various commodity such as massage appliance of eyes periphery.The asthenopic origin cause of formation can exemplify reading, watches operation attentively, observe the excess eye-using of operation etc. and psychentonia etc., especially the eyestrain that the VDT(Visual Display Terminal video display terminal sharply increasing along with popularizing of PC) operation causes becomes very many, wishes to address this problem.But, still do not have can be in operation easy to usely and at once improve the method for eyestrain's state, seeking new improvement method always.
The compound that eyestrain acts on is alleviated in having of having reported
Reported so far and can exemplify astaxanthin (non-patent literature 3,4), crocetin (non-patent literature 5) to eyestrain and the tired resultful compound of optic nerve, but these need long-term picked-up just can take effect, and cannot expect effect at once.Even reported the black currant anthocyanin (non-patent literature 6,7) of quick result, and also need a few hours just can take effect, and effect can not say very sufficient.
About resveratrol
Resveratrol is that Resveratrol is the compound that belongs to the stilbene phytoalexin group who comprises various trihydroxies and tetrahydroxystilbene.Resveratrol contains in Fructus Vitis viniferae and polygoni cuspidati,radix and Semen arachidis hypogaeae etc., wherein in Radix seu Herba Tetrastigmatis Hypoglauci, exists at most, well-known to have the material of good pharmacological effect.Up to the present the pharmacological effect about resveratrol has following report.In patent documentation 1, disclosed resveratrol for to the arthralgia of extremities joint and lumbago, the recurrence prevention of sciatica, the useful Orally administered composition of anesis.In patent documentation 2, disclosed resveratrol for activate to suppress the pharmaceutical composition increasing the weight of of blood circulation diseases by peroxisome proliferation response receptor alpha.In patent documentation 3, disclosed the compositions for the prevention of the symptom with flu and influenza class disease association and treatment use by resveratrol.In patent documentation 4, disclosed resveratrol for improving the edema of legs and feet, ice-cold food compositions.In patent documentation 5, disclosed using resveratrol as the material with AMPK activation, and the diet product that contain resveratrol have lipid metabolism activator, fat inhibitor, diabetes mellitus prevention improving agent, the loose inhibitor of liver, fatty liver inhibition.In patent documentation 6, disclosed using diet product that contain resveratrol etc. as antiinflammatory dietary supplement compositions.In patent documentation 7, disclose the diet product that contain resveratrol and there is the effect that reduces blood glucose value.In patent documentation 8, disclose resveratrol and there is the effect that improves endurance.In patent documentation 9, disclosed resveratrol for U.S. skin composition.In patent documentation 10, disclosed resveratrol as adiponectin secernent.
In addition, aspect the illness of eye, resveratrol was disclosed by silent message regulatory factor (サ ー チ ュ イ Application) activate, treat by this method (patent documentation 11,12,13) of the various symptoms of eyes.But, these documents be during with patient's long term administration to glaucoma and this class disease of degeneration of macula and to eyes direct injection or effect while pouring into as a specific example, and about easy and at once solve asthenopic item without any recording or hint.Also have, non-patent literature 8 has been reported in the test of end user's retinal pigment epithelium, resveratrol demonstrate there is antioxidative functional, hyper-proliferative inhibitory action, non-patent literature 9 has reported that resveratrol has the effect of the retina arteriole expansion of the pig that makes extraction.But, although because resveratrol is ingested, absorb and form sulphuric acid combination, glucuronic acid combination by intestinal tube, itself is not almost absorbed resveratrol, therefore, and according to these discoveries, resveratrol, so long as not directly injecting eye, just can not have instant effect to eyestrain.
Prior art document
[patent documentation]
[patent documentation 1] Japanese Patent Laid-Open 2001-72582 communique
[patent documentation 2] Japanese Patent Laid-Open 2003-300904 communique
The special table of [patent documentation 3] Japan Patent 2003-505500 communique
[patent documentation 4] Japanese Patent Laid-Open 2005-052085 communique
[patent documentation 5] Japanese Patent Laid-Open 2006-273834 communique
The special table of [patent documentation 6] Japan Patent 2006-528950 communique
[patent documentation 7] Japanese Patent Laid-Open 2007-126390 communique
[patent documentation 8] Japanese Patent Laid-Open 2007-145809 communique
[patent documentation 9] Japanese Patent Laid-Open 2008-088123 communique
[patent documentation 10] Japanese Patent Laid-Open 2008-255040 communique
[patent documentation 11] Japanese Patent Laid-Open 2006-298876 communique
The special table of [patent documentation 12] Japan Patent 2008-538215 communique
The special table of [patent documentation 13] Japan Patent 2009-529538 communique
Non-patent literature
The investigation report of the using method of [non-patent literature 1] technical report book: JEITA-EMF-R0504 " optic nerve is a tired " language etc.
[non-patent literature 2] man machine interface Conference Papers collection (ヒ ユ mono-マ Application イ Application タ mono-Off エ mono-ス シ Application Port ヅ ウ system Theory collected works), RONBUN No.2332,2006
[non-patent literature 3] Clinical Ophthalmology (Pro bed ophthalmology) 58(6), 1051-1054,2004
[non-patent literature 4] clinical medical (Pro bed medicine) 21(4), 431-436,2005
The science of [non-patent literature 5] vision (Visual Satoru science) 28(2), 77-84,2007
[non-patent literature 6] new ophthalmology (あ ら い ophthalmology) 23(1), 129-133,2006
[non-patent literature 7] new drug and clinical (new drug と Pro Bed) 56(2), 180-188,2007
[non-patent literature 8] chemistry and biological interaction (Chemico-biological interactions), Jan15,151(2), 143-149,2005
[non-patent literature 9] ophthalmology research and vision science (Investigative ophthalmology & visual science), Sep48(9), 4232-4239,2007
Summary of the invention
The object of this invention is to provide for alleviating the asthenopic compositions by generations such as VDT operations.
The invention provides and take the asthenopic compositions of alleviation that resveratrol is effective ingredient.
Inventors of the present invention, through after research repeatedly, find that resveratrol has the asthenopic effect of alleviation, thereby have completed the asthenopic compositions of alleviation that resveratrol is effective ingredient of take of the present invention.Compositions of the present invention is from buccal absorption, quick-acting alleviation eyestrain.
Invention effect
Compositions of the present invention have if with 10 minutes short like this time and only 1 picked-up just can alleviate asthenopic amazing effectiveness at once.In addition, compositions of the present invention, with 1～10mg picked-up, has the remarkable result more superior than the black currant anthocyanin of 50mg.More worth surprised, compositions of the present invention is absorbed by oral mucosa, only need rest in oral cavity and can bring into play effect.
Also have, resveratrol is the material being contained in Fructus Vitis viniferae, polygoni cuspidati,radix and Semen arachidis hypogaeae etc., and the impression in safe ， consumer is good.
Accompanying drawing explanation
Fig. 1, for confirming the test of the effect of resveratrol, the schematic diagram of the result that every 1 experimenter's near point instrument is measured.
Fig. 2, for the test of confirming the effect of resveratrol, the summary view of the result that near point instrument is measured.
Fig. 3, for confirming the schematic diagram of the effect of resveratrol to the fixed result of the dependent test of concentration, every 1 experimenter's near point instrumentation.
Fig. 4, for confirming the summary view of the effect of resveratrol to the fixed result of the dependent test of concentration, near point instrumentation.
Fig. 5, for confirming that resveratrol is by the schematic diagram of the result of the test of buccal absorption.
The specific embodiment
The invention provides and take the asthenopic compositions of alleviation that resveratrol is effective ingredient.Resveratrol is the compound shown in following structural formula.
The amount of application of every 1 time is 1～10mg preferably, is more preferably 1～6mg.
In addition, the invention provides take eyestrain is taken effect at once as the asthenopic compositions of above-mentioned alleviation of feature.At once taking effect refers to and uses latter 5 minutes～1 hour with interior performance effect, is more preferably and uses latter 10 minutes～30 minutes with interior performance effect.
Also have, the invention provides take and use the asthenopic compositions of above-mentioned alleviation as feature from the form of buccal absorption.From the form of buccal absorption, referring to by the form that is taken into compositions in oral cavity, is better, in oral cavity, the solution stirring containing compositions of the present invention, in the time of 1 minute～10 minutes, is absorbed to 10～30% specifically.But therefore, because compositions of the present invention is to organism safety, even if swallow thereafter, also can produces and absorb in the lump by the organ beyond in digestive appartus official rank oral cavity etc.
Also have, the invention provides the diet product that contain the asthenopic compositions of above-mentioned alleviation.Diet product are not limited, can exemplify food such as refreshment drink, cake, frozen confection, milk product, drinks and meat.In view of compositions of the present invention is from buccal absorption, be particularly preferably trapped in long chewing gum of time in oral cavity, confection, lamellar confection etc.In addition, diet product preferably according to the intake of the resveratrol of every 1 time be 1～10mg, the condition that is more preferably 1～6mg modulates.
Below, exemplify embodiment embodiments of the present invention are made to more specific description.
Embodiment 1
The mensuration of resveratrol to asthenopic effect
< test method >
Resveratrol is used all VINEATROL(registered trade marks of Co., Ltd. (サ Application Block ライ ト Co., Ltd.) system of Sang Bulaiyi) WD.These goods are in glycerin preparation, to contain 0.30% resveratrol (assay value).Each serving the used time, this glycerin preparation 2g(is contained to resveratrol 6mg) with distilled water, be settled to 10ml.
Black currant anthocyanin is used " カ シ ス エ キ ス-35 " (powder) of Ta Ma Biochemical Co., Ltd (タマ Biochemical Co., Ltd) system.In this powder, delphinidin-3-rutinoside, cyanidin-3-rutinoside, delphinidin-3-glucoside, this total content of 4 kinds of Cy-3-G are more than 35.0% (standard value).Each serving the used time, according to the total amounts of above-mentioned 4 kinds reach 35.0%, containing the condition of 50mg anthocyanin, powder 142.9mg is settled to 10ml with distilled water.
In whole 3 experimenters to 2 control period is set 18 days, 9 days phases of resveratrol picked-up, 14 days eluting phases, black currant anthocyanin 9 days phases of picked-up.To 1 experimenter control period is set 5 days, 5 days phases of resveratrol picked-up, 5 days eluting phases, black currant anthocyanin 5 days phases of picked-up.The mensuration of this in-test below implementing at dusk every day.
First, as measuring the investigation of implementing about near point instrument mensuration, eyestrain, physical fatigue before load.Then, apply the load of 20 minutes.That is, have on-2～-3 diopter lens, in bright room, implement the PC work (file typing) of 20 minutes.At this moment, from starting, to 10 minutes, not absorb anything in control period, in the resveratrol picked-up phase by resveratrol solution, black currant anthocyanin is kept in the mouth in the black currant anthocyanin picked-up phase, with tongue or cheek portion, carry out stirring (buccal absorption) in oral cavity, spue.Thereafter, then continue typing work 10 minutes.After stress test one finishes, implement immediately to measure after load, about the investigation of near point instrument mensuration, eyestrain, physical fatigue.
Near point instrument measure to use that eyes are open determines dioptric near point instrument D ' ACOMO(Wa Ku Co., Ltd. (ワ of Co., Ltd. Star Network)), according to operating instruction, carry out regulating power mensuration.Specifically, by sighting target, slowly near detected eyes (leading eye), indication experimenter continues photopic vision, reads the position that focus starts sighting target when fuzzy.If this is made as to a cm, the diopter (Diopter of unit that 100/a is near point; D), use this measured value to analyze.It is generally acknowledged, if eyestrain, because focal adjustments power declines, can know that the minimum distance (adjusting anomalistic distance) of looking thing becomes far gradually, can be based on this numerical evaluation eyestrain.In addition, near point instrument is determined at while measuring for 1 time and carries out 5 times, analyzes and uses its meansigma methods.
On the other hand, investigation for eyestrain, physical fatigue, relate to tired to eyes in asthenopic project, eyes pain, eyes fuzzy, shed tears, one's eyes became bloodshot, eyes are dry, heavy these 7 projects of sensation eyelid, relating in the project of physical fatigue headache, nose heave, shoulder is stiff, impatient these 4 projects, by not feeling, slightly feel, feel, have slightly keen sensation completely, having very strong these 5 levels of feeling to evaluate, not to be felt as 0 minute completely, have very strong be felt as 4 assign to scoring, analyze.
In the analysis of these experimental results, between group, relatively carry out the multiple check (Tukey) of population mean, with significance level 0.05, test.T(paired t is matched in the check of the measurement result before and after stress test is implemented) check, with significance level 0.05, test.
< result of the test >
During each of the result that 2 experimenters' control period 18 times, resveratrol and the black currant anthocyanin picked-up phase near point instrument of 9 times are measured and 1 experimenter, the measurement result of 5 times is as following table 1.By this pictorialization, be Fig. 1.
Table 1
Between # group, there were significant differences, p<0.05(multiple check)
* with before load compare that there were significant differences, p<0.05(paired t-test)
The result that 3 experimenters' near point instrument is measured gathers as shown in table 2.By this pictorialization, be Fig. 2.
Table 1
Between # group, there were significant differences, p<0.05(multiple check))
* with before load compare that there were significant differences, p<0.05(paired t-test)
Compare the remarkable effect of improving of diopter declining because applying load that resveratrol has absorbed group acknowledge with matched group.In black currant anthocyanin picked-up group, also obtained the result of remarkable improvement, but obviously resveratrol to improve effect high significantly.
On the other hand, as shown in table 3 about the survey result of eyestrain, physical fatigue.
Table 2
The variable quantity that value before load is deducted to the value gained after load carries out 3 experimenters' analysis, obtains the result as table 4.
Table 3
# with respect to matched group there were significant differences, p<0.05(multiple check)
B with respect to black currant anthocyanin picked-up group there were significant differences, p<0.05(multiple check)
Projects of matched group are all negative value, confirm to worsen, and resveratrol picked-up group are tired at eyes, eyes are dry, heavy, nose heave 4 projects of sensation eyelid are significantly improved.Black currant anthocyanin picked-up group is confirmed to be significantly improved in dry this 1 project of eyes.Resveratrol picked-up group is compared with black currant anthocyanin picked-up group, on sensation eyelid is heavy, confirms that there were significant differences, and obviously the body perception of resveratrol is high.
The confirmation of resveratrol to the concentration dependent of asthenopic effect
< test method >
To 2 experimenters control period is set 5 days, 5 days phases of 3mg resveratrol picked-up, 1mg resveratrol 5 days phases of picked-up.This duration of test is implemented mensuration similarly to Example 1 at dusk in every day.But, different from embodiment 1, in control period, buccal absorption water.
Resveratrol is every while taking for 1 time, by glycerin preparation 1g(containing resveratrol 3mg) or 0.33g(containing resveratrol 1mg) with distilled water, be settled to 10ml.
< result of the test >
Be that the situation of buccal absorption water is compared with contrasting, and compared 1, the buccal absorption of the resveratrol of 3mg obtains to asthenopic effect, during each of 2 experimenters, the near point instrument measurement result of 5 times is as shown in table 5.By this pictorialization, be Fig. 3.
Table 5
2 experimenters' result gathers as shown in table 6.By this pictorialization, be Fig. 4.
Table 4
Between # group, there were significant differences, p<0.05(multiple check)
* with before load compare that there were significant differences, p<0.05(paired t-test)
Confirmation by carrying out 1, the picked-up of 3mg resveratrol, diopter improves, and improvement degree and consumption have dependency, with respect to contrast, has all obtained the result of remarkable improvement.
On the other hand, the survey result of eyestrain, physical fatigue is as shown in table 7.
Table 5
In addition, the variable quantity that the value before load is deducted to the value gained after load carries out 2 experimenters' analysis, obtains the result as table 8.
Table 6
# with respect to matched group there were significant differences, p<0.05(multiple check)
Matched group is tired at eyes, be negative value in heavy, the nose heave project of sensation eyelid, confirms to worsen.On the other hand, the picked-up of the resveratrol by 1mg significantly improves on tired, nose heave 2 of eyes.Do not find the dependency of improvement degree to consumption, but compared with the control, all confirm for two groups to be improved, by the picked-up of 1～3mg, eyestrain, physical fatigue obviously improve.
Embodiment 3
By buccal absorption, test the buccal absorption of confirming resveratrol
In order to confirm to absorb resveratrol in oral cavity, carry out resveratrol solution not being drunk and in oral cavity, with tongue and cheek, stir after certain hour the buccal absorption test of the survival rate of the resveratrol in the solution that investigation spues.
< test method >
According to the intake of the resveratrol of taking for every 1 time, reach 1 or the condition of 2mg, weigh the resveratrol preparation of aequum, heat to the 5mM phosphate buffer (pH6.5) of 37 ℃ and be settled to 10ml, make testing liquid.Experimenter (2) gargles with distilled water, quiet 5 minutes., above-mentioned testing liquid 10ml kept in the mouth, do not drink into but use cheek and tongue to stir certain hour with the speed in 1 time/1 second thereafter.By the intraoral solution 50ml centrifuge tube (Off ア Le コ Application チ ユ mono-Block) that spues completely as much as possible, with 5mM phosphate buffer (pH6.5), wash one's face and rinse one's mouth 3 times (altogether using the buffer of 20ml 3 times), spue at once.Merge the solution spuing, measure the amount of residual resveratrol.Specifically, merge the solution spue, with 5mM phosphate buffer (pH6.5), be settled to 50ml, the acetonitrile of interpolation equivalent, carries out after centrifugalize with 3000rpm, the condition of 10 minutes, 4 ℃, by 0.45 μ m membrane filtration for supernatant, carries out HPLC analysis.
< result of the test >
Result of the test to 3 times is analyzed, and obtains the result as table 9.By its pictorialization, be Fig. 5.
Table 7
< is used the testing liquid of 1mg/10ml, stirs the situation > of 1,5,10 minute
< stirs the test > of 5 minutes with initial concentration 1,2mg/10ml
By these result of the tests, shown, the absorbtivity of the resveratrol in oral cavity has concentration dependent, and in 5 minutes stirring tests of 1～2mg/10ml, estimation has 20～25% absorbance.
Below, exemplify embodiment and illustrate in greater detail product of the present invention, but these embodiment do not limit the scope of product of the present invention.
Use the preparation that approximately contains 8% resveratrol, by common method, manufacture chewing gum, confection, lamellar confection.Its formula is below shown.
In addition, the intake of every 1 time of each diet product is made as chewing gum 1 (3g), confection 1 (5.4g), 4 of lamellar confections (4.0g), reaches 1～10mg modulate according to the intake that makes resveratrol.
According to following formula, manufacture chewing gum.
Embodiment 5
According to following formula, manufacture chewing gum.
According to following formula, manufacture chewing gum.
Embodiment 7
According to following formula, manufacture confection.
According to following formula, manufacture confection.
Embodiment 9
According to following formula, manufacture lamellar confection.
According to following formula, manufacture lamellar confection.
Embodiment 11
According to following formula, manufacture lamellar confection.
This application is advocated the priority of No. 2011-144389th, the Japanese patent application of filing an application on June 29th, 2011, quotes its content as the part of this application.
Claims (5)
1. the asthenopic compositions of alleviation that the resveratrol of take is effective ingredient.
2. the asthenopic compositions of alleviation as claimed in claim 1, is characterized in that, eyestrain is taken effect at once.
3. the asthenopic compositions of the alleviation as described in any one in claim 1 or 2, is characterized in that, with the form from buccal absorption, uses.
4. the diet product that contain the asthenopic compositions of alleviation described in any one in claim 1～3.
5. diet product as claimed in claim 4, is characterized in that, reach the condition modulation of 1～10mg according to the intake of the resveratrol of every 1 time.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-144389 | 2011-06-29 | ||
| JP2011144389A JP5848042B2 (en) | 2011-06-29 | 2011-06-29 | Eye fatigue inhibiting composition and food and drink containing the same |
| PCT/JP2012/004115 WO2013001786A1 (en) | 2011-06-29 | 2012-06-26 | Eye fatigue suppression composition and food and drink containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103635185A true CN103635185A (en) | 2014-03-12 |
Family
ID=47423708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280031891.6A Pending CN103635185A (en) | 2011-06-29 | 2012-06-26 | Eye fatigue suppression composition and food and drink containing same |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5848042B2 (en) |
| KR (1) | KR101956403B1 (en) |
| CN (1) | CN103635185A (en) |
| TW (1) | TWI605813B (en) |
| WO (1) | WO2013001786A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106106976A (en) * | 2016-06-17 | 2016-11-16 | 甘肃寿鹿山药业有限公司 | A kind of resveratrol soft sweet and preparation method thereof |
| CN106470694A (en) * | 2014-05-27 | 2017-03-01 | Ss制药株式会社 | For improving the Orally administered composition of the General Symptomies including cold sensitivity |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6533784B2 (en) * | 2014-06-25 | 2019-06-19 | 協和発酵バイオ株式会社 | Eye fatigue improver |
| JP7140533B2 (en) * | 2017-08-30 | 2022-09-21 | 東洋精糖株式会社 | Composition for ameliorating asthenopia or for ameliorating decreased focusing ability of eyes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US20090175803A1 (en) * | 2008-01-08 | 2009-07-09 | David Rubin | Method and compositions for administering resveratrol and pterostilbene |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20010540A1 (en) | 1999-07-30 | 2001-05-15 | Procter & Gamble | COMPOSITION OF STYLBENE PHYTOALEXINS USEFUL FOR PROPHYLAXIS AND TREATMENT OF SYMPTOMS ASSOCIATED WITH COLD AND INFLUENZA-SIMILAR DISEASES |
| JP2001072582A (en) | 1999-09-07 | 2001-03-21 | Sunstar Inc | Functional oral composition |
| JP2002293736A (en) * | 2001-03-30 | 2002-10-09 | Sunstar Inc | Maillard reaction inhibitor and composition containing the same |
| JP2003300904A (en) | 2002-04-05 | 2003-10-21 | National Cardiovascular Center | Medicinal composition for suppressing progress of circulatory disturbance |
| JP2006298876A (en) * | 2005-04-25 | 2006-11-02 | Saisentan Igaku Kenkyusho:Kk | Composition containing sirtuin-activating agent and used for treating various eye diseases |
| KR101143719B1 (en) | 2003-05-27 | 2012-05-09 | 디에스엠 아이피 어셋츠 비.브이. | Novel nutraceutical compositions and use thereof |
| JP2005052085A (en) | 2003-08-05 | 2005-03-03 | Orbis Inc | Food composition |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| JP2006273834A (en) | 2004-06-28 | 2006-10-12 | Kao Corp | Ampk activator |
| US20070014833A1 (en) | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| CN101365431A (en) * | 2005-10-14 | 2009-02-11 | 帝斯曼知识产权资产管理有限公司 | Novel use of nutraceutical compositions comprising resveratrol |
| JP4739161B2 (en) * | 2005-10-26 | 2011-08-03 | 花王株式会社 | Endurance improver |
| JP2007126390A (en) | 2005-11-02 | 2007-05-24 | Mercian Corp | Agent for reducing blood glucose level |
| JP5281234B2 (en) * | 2006-06-27 | 2013-09-04 | ポーラ化成工業株式会社 | Orally administered composition for the improvement and prevention of fatigued eyes due to ciliary overtension |
| JP2008088123A (en) | 2006-10-03 | 2008-04-17 | Oriza Yuka Kk | Skin-beautifying composition |
| JP2008255040A (en) | 2007-04-03 | 2008-10-23 | Shiseido Co Ltd | Adiponectin production promoter |
-
2011
- 2011-06-29 JP JP2011144389A patent/JP5848042B2/en active Active
-
2012
- 2012-06-26 CN CN201280031891.6A patent/CN103635185A/en active Pending
- 2012-06-26 KR KR1020147001554A patent/KR101956403B1/en active IP Right Grant
- 2012-06-26 WO PCT/JP2012/004115 patent/WO2013001786A1/en active Application Filing
- 2012-06-27 TW TW101122987A patent/TWI605813B/en active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US20090175803A1 (en) * | 2008-01-08 | 2009-07-09 | David Rubin | Method and compositions for administering resveratrol and pterostilbene |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106470694A (en) * | 2014-05-27 | 2017-03-01 | Ss制药株式会社 | For improving the Orally administered composition of the General Symptomies including cold sensitivity |
| US10695392B2 (en) | 2014-05-27 | 2020-06-30 | Ssp Co. Ltd | Oral composition for improving systemic symptoms including sensitivity to cold |
| CN106106976A (en) * | 2016-06-17 | 2016-11-16 | 甘肃寿鹿山药业有限公司 | A kind of resveratrol soft sweet and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013010714A (en) | 2013-01-17 |
| TWI605813B (en) | 2017-11-21 |
| WO2013001786A1 (en) | 2013-01-03 |
| KR101956403B1 (en) | 2019-03-08 |
| JP5848042B2 (en) | 2016-01-27 |
| KR20140048212A (en) | 2014-04-23 |
| TW201315460A (en) | 2013-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Greenway et al. | A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report | |
| TWI583390B (en) | Ellagitannins rich extracts composition | |
| CN103635185A (en) | Eye fatigue suppression composition and food and drink containing same | |
| WO2006033412A1 (en) | Alleviator for radiation disorder | |
| US20150140112A1 (en) | Composition comprising extract of mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis | |
| US20180104269A1 (en) | Composition for suppressing muscular fatty change | |
| Bianchetti et al. | Sarcopenia in the elderly: from clinical aspects to therapeutic options | |
| CN101306009A (en) | Function food for protecting nourishing the liver | |
| CN102770150B (en) | Composition for promoting the activity of peroxisome proliferator-activated receptor-delta | |
| CN103877097A (en) | Novel use of ursolic acid derivative | |
| Soni et al. | EFFECT OFALOE VERA JUICE ON DIABETIC AND DIABETIC RETINOPATHY SUBJECTS | |
| Wang et al. | Progress in research on physiological function and mechanism of oral hyaluronic acid. | |
| WO2015028456A1 (en) | PPAR modulators | |
| JP2010168399A (en) | Pharmaceutical for controlling elevation of blood sugar | |
| Kumar et al. | Effect of coffee on blood pressure and electrocardiographic changes in young and elderly healthy subjects | |
| JP2006213657A (en) | HUMAN beta3-ADRENALIN RECEPTOR AGONIST AGENT | |
| JPWO2005082391A1 (en) | Human β3 adrenergic receptor agonist | |
| AU2016323779B2 (en) | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma | |
| Amer et al. | Obeticholic Acid and Insulin Sensitivity in Overweight Patients with Prediabetes | |
| Godbole et al. | Role of Sneha kalpana (Oil based formulation) in the management of Vataja Prameha (Vata predominance Prameha) wsr to Khadira-kramuka kashaya siddha taila | |
| Alekberova et al. | Evaluation of effectiveness of the use of toothpastes in treatment of non-carious teeth diseases | |
| CN104887757B (en) | The Chinese medicine composition and massage cream of freeing vessels and nourishing heart | |
| Rosyid et al. | A Combination Supplement of Bitter Melon Extract (momordica charantia l.) with Snakehead Fish (channa striata) Powder has no Effect as an Anti-glycation Agent in type 2 Diabetes Mellitus | |
| CN105395680B (en) | It is a kind of to treat neurasthenic Chinese medicine composition and its preparation method and application | |
| Hill et al. | Minocycline-induced interstitial nephritis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140312 |